Tesamorelin + Ipamorelin
GHRH analog + GHSR agonist blend
A vendor blend combining an approved indication-specific medicine with an unapproved secretagogue; the mixture itself is not an approved product.
Mechanism
Combined GHRHR and GHSR stimulation
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Human evidence is absent, limited or not confirmatory
Anecdotal schedules are excluded because frequency of online repetition does not establish identity, safety, or a clinically meaningful dose.
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Common bedtime blend schedule | 1 mg / 200 mcg | One administration/day | Once daily | Bedtime, often fasted | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
No approved fixed-ratio blend exists. Component amounts and final concentrations must be known separately.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Community-Reported Preparation Notes
Diluent reports, visible-change signals, and formulation sensitivity—kept separate from validated product instructions.
Bacteriostatic water is the most frequently described community choice for the combined vial.
Sterile water and acidified laboratory approaches are discussed for individual components, not validated for every finished blend.
- Community consistency
- Mixed
- Cloudiness / gel signal
- Higher-priority watch
Tesamorelin content, total concentration, pH, temperature, component ratio, and agitation.
The blend inherits tesamorelin's formulation concern, but cannot inherit a validated method from either ingredient alone.
Visible-change discard rule: Do not use or attempt to salvage material with persistent cloudiness, strings, flakes, precipitate, unusual thickening, or gel formation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
No approved fixed-ratio blend exists. Component amounts and final concentrations must be known separately.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Tesamorelin labeling and ipamorelin research do not establish safety, efficacy or dosing for the blend.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.